Here, by restricting Sucla2 mutagenesis to the murine skeletal muscle via the Cre/loxP system [15, 16, 17], the development of a viable model of SUCLA2‐deficient mitochondrial myopathy has been achieved. This evidence concerns the gene SUCLA2 and Mitochondrial myopathy.